Management of Hemoptysis with Aerosol Therapies

Guideline-Based Approach to Aerosol Therapies in Hemoptysis

The American Thoracic Society provides guidance on managing aerosol therapies during hemoptysis, recommending that for scant hemoptysis (<5 mL), aerosol therapies should NOT be stopped (median score 0, good consensus) 1, 3
For mild-to-moderate hemoptysis, aerosol therapies should be withheld only in rare circumstances, though specific mucolytics like hypertonic saline showed higher discontinuation ratings 1, 2
For massive hemoptysis, hypertonic saline should be stopped due to its propensity to induce cough and potentially exacerbate bleeding 1, 2, 3

The American Journal of Respiratory and Critical Care Medicine defines hemoptysis volume as scant: <5 mL 4, mild-to-moderate: 5-240 mL per 24 hours 4, and massive: >240 mL per 24 hours 4, 5
For mild-to-moderate hemoptysis, discontinue acetylcysteine and other mucolytics that increase secretion volume and induce cough 1, 2
For massive hemoptysis, immediately stop all mucolytics including acetylcysteine 1, 2, 3

The American College of Chest Physicians recommends central cough suppressants (codeine, dextromethorphan) for short-term symptomatic relief in chronic bronchitis, though evidence is limited 6, 7